WednesdaySep 14, 2022 9:30 am

Cepton, Inc. (NASDAQ: CPTN) Remains Committed to Delivering Enhanced Safety for All Drivers; Works with Top 10 Global Automotive OEMs to Commercialize Lidar

Evidence suggests that current ADAS solutions relying on cameras for perception are not yet safe enough due to camera’s limited capabilities of providing accurate perception data 24/7In a recent article authored for Forbes, Cepton's co-founder and CEO Jun Pei calls for widespread adoption of sensor suites that include complementary technologies–including lidar, camera, and radar–that seamlessly work together to enhance safety for driversCepton remains committed to deploying lidar in all vehicles with the goal of making the driving experience safer and more efficient for all road participants; expands collaboration with Koito to extend beyond its current OEM series production program "If…

Continue Reading

WednesdaySep 14, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension

Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIsThe company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directorsDr. Turkel, who brings over 20 years’ experience, has previously formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans, as well as led global development programs for pharmaceutical and biologic treatmentsDr. Turkel will lend her drug registration experience and regulatory expertise to Lexaria at a time when the company is journeying toward regulatory approval for DehydraTECH-CBD, its drug candidate for the treatment…

Continue Reading

TuesdaySep 13, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomasGlioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosisCNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and stable diseaseThe…

Continue Reading

TuesdaySep 13, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC), Cannabis Brand Builder, is Ramping Up its HR Productivity and Effectiveness One Appointment at a Time

A 2017 study by McKinsey & Company showed that high performers tend to be 400% more productive than average ones. This outlook has shaped Flora Growth’s hiring strategy for 2022, with the appointment of several key individuals whose proven talents and productivity are seen as critical to the company’s goal of delivering the most compelling customer experiences, most recently with the appointment of Elshad Garayev as Flora’s Chief Financial Officer (“CFO”)Mr. Garayev’s appointment marks the latest addition to a growing list of leaders ready to elevate the company to another level of international performance In a study conducted in 2017 by…

Continue Reading

MondaySep 12, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) ‒ Experts Confirm Lidar Technology Provides Superior Automotive Safety Compared to Camera-only Systems

Consensus among autonomous vehicle experts increasingly lean in favor of implementing lidar solutions to promote AV safetyHD cameras only provide raw image data in 2D; lidar uses laser technology to determine exact distance and location of objectsCepton produces state-of-the-art, intelligent, lidar-based applications for AV, ADAS, smart cities, connected spaces, and smart industrial applicationsCPTN engaged with top 10 global automotive OEMs, including GM and Ford Expert opinions concerning autonomous vehicle (“AV”) safety are leaning in favor of using lidar (light detection and ranging) technologies in addition to HD cameras, a positive development for Cepton (NASDAQ: CPTN), a developer of lidar-based solutions…

Continue Reading

MondaySep 12, 2022 12:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products

Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EUThe patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness fieldAdditional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia, obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictionsThe global market of CBD for health and wellness…

Continue Reading

FridaySep 09, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumorsGlioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cureCNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, BerubicinBerubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclinesCNS has shown evidence of slowing disease progression…

Continue Reading

ThursdaySep 08, 2022 9:45 am

Cepton, Inc.’s (NASDAQ: CPTN) Short-Range Lidar Nova Aims to Eliminate Blind Spots for Autonomous Vehicles; Plans to Exhibit Tech During IAA Transportation Conference

Cepton, in collaboration with ZKW Group GmbH, plans to showcase its Nova lidar headlamp integration into a ZKW heavy-duty truck headlamp at the IAA Transportation Conference (Sept. 20-25, 2022)Nova is an award-winning, miniature, wide field of view, near-range lidar sensor that provides high resolution 3D imaging in a compact form factor Nova integrates seamlessly around vehicles to provide 360-degree perception boosting blind spot detection, which is becoming a mandated vehicle safety feature The success of autonomous vehicles (“AV”) and advanced driver assistance systems (“ADAS”) hinges on technologies that make 360-degree intelligent perception possible. Cepton (NASDAQ: CPTN), a Silicon Valley innovator of…

Continue Reading

ThursdaySep 08, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Names New CFO, Process for Ensuring Smooth Transition Amid Company’s Global Growth

Global cannabis brand-builder Flora Growth recently named a former Amazon financial executive as its new CFO Elshad Garayev will work with outgoing CFO Lee Leiderman to ensure a smooth transition of responsibility amid finalization of Flora’s mid-year financial filing with the SECFlora Growth is headquartered in Canada with cultivation operations centered in Colombia, where recent government administrations have opened regulatory processes for exporting cannabis derivatives for the health and wellness marketsThe company continues to expand its operations internationally for sales in the UK and Europe generally, Australia, and throughout the Americas Global cannabis brand-builder Flora Growth (NASDAQ: FLGC) has steadily built…

Continue Reading

WednesdaySep 07, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 millionThe company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar yearCNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics approvals specifically…

Continue Reading

Contact us: (310) 299-1717